OTX2-AS1: A Potential Drug Target and Biomarker (G100309464)

Target Name: OTX2-AS1

NCBI ID: G100309464

Other Name(s): OTX2 antisense RNA 1 (head to head) | OTX2OS1 | OTX2-AS1 variant 1 | OTX2 antisense RNA 1 (head to head), transcript variant 1

OTX2-AS1: A Potential Drug Target and Biomarker

Oncogenic transformation of stem cells to cancer is a significant public health concern, resulting in the loss of thousands of lives each year. The process of oncogenic transformation occurs when stem cells undergo a series of changes that lead to the formation of cancerous cells. One of the major risk factors for cancer is the over-expression of stem cell-specific genes, including the Oncogene OTX2.

OTX2 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. OTX2 has been shown to play a crucial role in the development and progression of various diseases, including cancer.

Potential Drug Target

OTX2 is a key regulator of the stem cell proliferation cycle and has been shown to promote the self-renewal and survival of stem cells. It has been shown to play a role in the development and progression of various diseases, including cancer. By targeting OTX2, researchers have been able to inhibit the process of oncogenic transformation and potentially treat various diseases.

Biomarker

OTX2 has also been identified as a potential biomarker for various diseases, including cancer. The expression of OTX2 has been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown thatOTX2 has been associated with cancer-related outcomes, such as poor prognosis and the development of metastasis.

In conclusion, OTX2 is a potential drug target and biomarker for various diseases, including cancer. Further research is needed to fully understand the role of OTX2 in disease progression and the development of new treatments.

Protein Name: OTX2 Antisense RNA 1 (head To Head)

More Common Targets